New drug combo aims to spare seniors from chemo

NCT ID NCT05025423

Terminated Disease control Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested a combination of two drugs, venetoclax and rituximab, as a first treatment for people over 60 with mantle cell lymphoma. The goal was to see if this chemo-free approach could shrink or control the cancer. However, the study was stopped early after enrolling only 7 participants, so we don't have enough data to know if it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: venetoclax and rituximab
What this could lead to: If successful, this could offer a chemotherapy-free initial treatment option for older patients with mantle cell lymphoma.
What could go wrong: The trial was terminated early with only 7 participants, so results are very limited. It is unclear if the combination is effective or safe enough to replace standard treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MANTLE CELL LYMPHOMA

Contacts and locations

Locations

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Baltimore, Maryland, 21231, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.